N/A
Completed N=60
Ginger Capsules for the Acute Treatment of Migraine Attacks
Source: ClinicalTrials.gov NCT02568644 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcomePrimary: Change in Headache Severity. — 0.81; 0.97 units on a scale
Summary
The main objective of the study was to evaluate ginger efficacy as an adjuvant to ketoprofen for the treatment of headache and other symptoms related with migraine attacks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Headache Severity. |
0.43; 0.90 | — |
| SECONDARY Change in Serum Levels of Biomarkers. |
6077; 6503 | — |
Eligibility Criteria
- Inclusion Criteria:
- Migraine diagnosis for at least one year;
- Migraine attack with moderate or severe pain intensity;
- One to six migraine attacks per month.
- Exclusion Criteria:
- Patients with headaches not characterized as migraine;
- Pregnant or lactating women;
- Fertile and sexually active women who do not use contraception;
- Abuse of painkillers, alcohol or drugs;
- People with hypersensitivity to ginger;
- People with other neurological diseases;
- People in use of anticoagulant drugs;
- People who have started the disease after 50 years old.
Data sourced from ClinicalTrials.gov (NCT02568644). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.